分享好友 环球市场首页 环球市场分类 切换频道

Drug-coated Balloon Catheter Market (2023 - 2030 )

2023-09-2700

Report Overview

The global drug-coated balloon catheter market size was valued at USD 642.0 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.0% from 2023 to 2030. The drug-coated balloon catheters are also known as drug-eluted balloon catheters which are designed to dilate the stenotic coronary artery and used in the treatment of in-stent restenosis (ISR). The factors such as rise in demand for minimally invasive procedures and innovations in drug-coated/drug-eluting balloons are expected to contribute to growth of the market. The growing older population has had a substantial impact on market share. Additionally, it has been demonstrated that older individuals are more likely to experience health problems, making them more susceptible to diseases like peripheral and cardiovascular abnormalities. Drug-coated/drug-eluting balloons can treat and correct these problems.

Drug-coated/drug-eluting balloons are used by patients to treat coronary atherosclerosis and prevent restenosis. The aforementioned factors are therefore expected to increase consumer demand for drug-coated/drug-eluting balloons.

The COVID-19 pandemic had a major impact on the drug-eluting balloon catheters sector, due to the postponement of peripheral, interventional, along with cardiovascular surgical procedures. The treatment of coronavirus patients was given top priority in many countries to keep the system from becoming overburdened by a large number of cases. Additionally, to prioritize resources for the treatment and care of pandemic patients, hospitals postponed all non-emergency treatments, including catheterization.

Additionally, the prevalence of chronic diseases is increasing, and the desire for minimally invasive surgical procedures is increasing the need for technologically advanced products in healthcare settings. Market growth has spurred recently, thanks to the use of cutting-edge products and surgeries that have enhanced life expectancy as well as sped up diagnostic procedures among the senior demographic base. Market participants are focusing on developing affordable, precise, and efficient drug-eluting/drug-coated balloon catheters to improve medication delivery. Over the projection period, this effort will boost the market expansion of drug-eluting/drug-coated balloon catheters.

Technology development has led to the development of novel items that produce superior results. For instance, Cardiovascular Systems introduced advanced peripheral balloon catheters for complicated lesions in April 2021. Governments also provide funding to companies for research on new technology and safety investigations. This continues to push innovation. For instance, Terumo Corporation stated in April 2022 that the trial using its most recent bobby balloon guide catheter has enrolled its first patient. Thus, it will propel the market growth.

Type Insights

The paclitaxelsegment held 96.01% of the global market share in 2022, accounting for the largest proportion of the market.This is primarily due to the increasing cases of cardiovascular illness. As per the world health organization, cardiovascular disease causes 17.9 million deaths annually, making it the leading cause of death worldwide. By 2030, this number is predicted to increase to over 23.6 million, indicating the urgent need for the advancement of heart-related surgeries. As more medical professionals and healthcare facilities use cutting-edge tools to complete complex interventional procedures. Peripheral vascular balloon catheters enhance the safety of patients throughout surgical treatments by assisting with drug delivery, restricting the growth of vascular smooth muscle cells amid neointimal growth & development, and inhibiting restenosis.

The Sirolimus segmentis expected to grow at a lucrative rate during the forecasted period. As an alternate drug-eluting device to the currently available paclitaxel coat balloon platforms for the management of peripheral artery disease (PAD), sirolimus-coated balloons (SCB) have shown tremendous potential. They have undergone thorough preclinical testing, showing both anti-restenotic efficacy and clinical safety when used to treat coronary artery disease. Thus, it will be propelling the demand for sirolimus among healthcare professionals and further boost the segment growth in coming years.

Product Insights

The peripheral vascular disease segment held 72.64% of the global market share in 2022, accounting for the largest proportion of the market. Peripheral artery disease (PAD), affects more than 200 million individuals worldwide and is linked to high mortality and morbidity, is addressed in the American Heart Association's 2021 report. The aging of the world's population will probably lead to an increase in PAD cases in the future. Therefore, as per the statistics, the number of PAD is growing more quickly, which ultimately is pushing the market growth.

The coronary artery disease segment is expected to grow at a lucrative rate during the forecasted period. The market is mainly influenced by the rise in coronary artery disease prevalence around the world, rising funding for research and development of devices for the condition, and an increase in comorbid conditions including atherosclerosis and hypertension. Due to the increased risk of chronic diseases among the elderly, the geriatric population is predicted to have a substantial impact on the market under consideration. The percentage of the world's population 60 years of age and older is expected to rise from 12% to 22% between 2015 and 2050, based on the World Health Organization Facts of 2021. 80% of the elderly population worldwide will reside in countries with low or middle incomes by 2050. In comparison to earlier times, the population is aging significantly more quickly, which contributes to the segment's continued expansion.

End-Use Insights

The hospital segment held 40.83% of the global market share in 2022, accounting for the largest proportion of the market. Due to a greater amount of cardiac & peripheral disease treatments carried out in hospitals. Additionally, the demand for these devices from various settings worldwide is being fueled by suitable compensation provided by these settings as well as the rapid growth of healthcare as well as hospital infrastructure, particularly throughout developing nations. Thus, it will propel the market growth.

Ambulatory surgical centersare expected to grow at a lucrative rate during the forecasted period. The utilization of drug-eluting balloon catheters in ambulatory surgery centers is increasing due to the many benefits they offer. These advantages include shorter operation times, enhanced effectiveness, and better patient outcomes. Therefore, an increasing number of ASCs are opting to use this technology.

Regional Insights

North America accounted for the largest share of the drug-coated balloon catheter market in 2022, with 37.41%. The significant market share in North America can be attributed to several factors, the availability of various major manufacturers, the launch of new, technologically advanced devices, and favorable reimbursement regulations are all important factors. The American Heart Association estimates that over 500,000 percutaneous coronary procedures, including percutaneous transluminal coronary interventions, are carried out annually in the US. Additionally, rising government expenditure on health care in the U.S. is promoting market expansion.

However, during the anticipated time, the Asia Pacific region is anticipated to have rapid expansion. This can be ascribed to the rise in healthcare expenditure as well as an increase in the incidence of cardiovascular disorders. As per Biomedcentral, cardiovascular disease affects approximately one out of every five individuals in China. In addition, it is anticipated that the demand in the region will be driven by an aging population in countries like China & Japan and rising disposable income. The expansion of the industry in the area is also being aided by the rise of health tourism in emerging countries.

Key Companies & Market Share Insights

The continuous demand for drug-coated balloon catheters by multiple end-users has created numerous market opportunities for major players to capitalize on. For instance, in April 2023, the innovative MagicTouch Sirolimus Coated Balloon (SCB) from Concept Medical Inc. has been given an Investigational Device Exemption (IDE) clearance by the US Food & Drug Administration for the medical treatment of small vessels (SV) in coronary arteries. Some prominent players in the global drug-coated balloon catheter market include:

Recent Development

Drug-coated Balloon Catheter Market

举报
收藏 0
评论 0